疫苗反应原性对成人流感疫苗接种意愿影响的系统综述
该系统综述检索1979年至2024年5月6个数据库的文献,评估疫苗反应原性(局部和全身症状)对成人流感疫苗接种意愿的影响。共纳入462篇文献,其中353篇(76%)报告一般副作用作为不接种原因,仅61篇(13%)具体报告反应原性。研究设计异质性大且高质量研究缺乏,无法得出确定结论。
要点
- 副作用常被报告为不接种流感疫苗的原因,但专门研究反应原性的高质量证据很少
- 经历局部或全身反应者未来接种意愿可能更低,但研究异质性限制结论强度
- 需更多高质量研究理解反应原性影响,以指导提升接种覆盖率的策略
核心结论
- 副作用常被引为不接种原因,但专门探讨反应原性对流感疫苗意愿影响的高质量研究匮乏。
- 多数研究提示经历反应原性与未来接种意愿降低有关,但研究设计和质量异质性妨碍确定结论。
研究设计与样本
- 系统综述,检索6个数据库1979年至2024年5月发表的文献。
- 纳入标准采用SPIDER框架,限定为 peer-reviewed 成人(≥18岁)流感疫苗接种研究。
- 共绘制462篇文献,按副作用报告方式分类,并使用NIH质量评估工具评价质量。
主要发现
- 462篇中353篇(76%)报告感知或经历的一般副作用作为不接种原因。
- 48篇(10%)报告一般副作用加感染流感,61篇(13%)报告疫苗反应原性。
- 61篇报告反应原性的研究中,11篇(18%)报告经历和预期反应原性,12篇(20%)报告预期,38篇(62%)报告经历。
- 质量评估多数为fair(n=57),good 2篇,poor 2篇。
临床怎么用
- 在与成人沟通流感疫苗接种时,应主动告知可能的局部和全身反应及其通常短暂的性质。
- 针对曾经历反应原性者,可提供针对性咨询以减少其对后续接种的顾虑。
局限性
- 专门探讨反应原性影响的高质量研究缺乏。
- 纳入研究的设计和质量异质性大,妨碍得出确定结论。
- 多数研究质量为fair,good和poor研究各仅2篇。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the quantity and quality of studies investigating the impact of vaccine reactogenicity, defined as local (e.g. injection-site pain, redness, swelling) and systemic (e.g. fever, myalgia, headache) symptoms, on willingness to accept influenza vaccination. METHODS: A systematic review was conducted on literature published from 1979 to May 2024 using 6 databases. Inclusion and exclusion criteria were defined using the SPIDER framework., Studies were restricted to peer-reviewed studies of adults (≥18 years) examining influenza vaccination. Included publications were categorised according to how vaccine side effects were reported i.e. general side effects, general side effects plus contracting influenza, or reactogenicity. National Institutes of Health (NIH) quality assessment tools were used to assess the quality of included publications. RESULTS: Of 462 publications charted, 353 (76 %) reported perceived or experienced general side effects as reasons for non-vaccination; 48 (10 %) reported general side effects and contracting influenza; and 61 (13 %) reported vaccine reactogenicity. Of the 61 studies reporting or specifying reactogenicity, 11 (18 %) reported both experienced and anticipated reactogenicity, 12 (20 %) reported anticipated reactogenicity, and 38 (62 %) reported experienced reactogenicity. Most studies were rated fair quality (n = 57), with two good and two poor. Twenty-one studies investigated associations between reactogenicity and uptake (willingness or actual vaccination). Of these, 11 examined experienced reactogenicity; the majority (9 of 11) found that individuals who experienced local or systemic reactions perceived themselves to be less likely to accept vaccination in future seasons. CONCLUSIONS: While side effects are frequently cited as reasons for non-vaccination, there is a dearth of high-quality studies specifically addressing the impact of reactogenicity on influenza vaccine willingness. Although most suggest a link between experienced reactogenicity and reduced future intention to vaccinate, heterogeneity in study design and quality precludes firm conclusions. Understanding the implications of reactogenicity is essential to inform strategies that improve coverage and guide intervention design.
引用
- Lister H, Farquharson K, Seale H, et al. A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults. Vaccine. 2026. PMID: 41505873. doi:10.1016/j.vaccine.2026.128195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。